BioArctic
302.40 SEK
-1.43 %
Less than 1K followers
BIOA B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for BioArctic
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 281.8 | 62.3 | 23.1 | 228.3 | 616.0 | 257.4 | 1,999.1 |
| growth-% | -77.9 % | -62.9 % | 886.3 % | 169.8 % | -58.2 % | 676.8 % | |
| EBITDA | 121.7 | -74.0 | -126.6 | -2.8 | 271.1 | -171.1 | 1,271.6 |
| EBIT | 112.5 | -85.0 | -139.7 | -17.4 | 252.6 | -228.5 | 1,258.8 |
| Profit before taxes | 113.0 | -86.7 | -140.5 | -11.2 | 276.5 | -189.5 | 1,255.6 |
| Net income | 88.5 | -68.5 | -119.8 | -11.2 | 229.3 | -177.1 | 1,022.3 |
| EPS | 1.00 | -0.78 | -1.36 | -0.13 | 2.60 | -2.00 | 11.55 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 |
| Dividend ratio | 0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % | -0.0 % | 17.3 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 43.2 % | -118.7 % | -547.0 % | -1.2 % | 44.0 % | -66.5 % | 63.6 % |
| EBIT-% | 39.9 % | -136.4 % | -603.7 % | -7.6 % | 41.0 % | -88.8 % | 63.0 % |
| ROE | 9.1 % | -7.6 % | -15.2 % | -1.4 % | 21.9 % | -19.8 % | 52.0 % |
| ROI | 7.5 % | -6.5 % | -13.3 % | -1.3 % | 19.3 % | -15.9 % | 39.7 % |